Switch to: References

Add citations

You must login to add citations.
  1. Avoiding Exceptionalism and Silver Bullets: Lessons from Public Health Ethics and Alzheimer’s Disease.Ignacio Mastroleo & Timothy Daly - 2021 - American Journal of Bioethics 21 (12):25-28.
    Lynch et al.’ s work “Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?” is an essential c...
    Download  
     
    Export citation  
     
    Bookmark  
  • What is a reasonable framework for new non-validated treatments?Gert Helgesson - 2020 - Theoretical Medicine and Bioethics 41 (5):239-245.
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease.Timothy Daly & Stéphane Epelbaum - 2023 - American Journal of Bioethics Neuroscience 14 (3):332-335.
    It is a tale of two Pfizers. In 2018 they abandoned research into the leading cause of dementia, Alzheimer’s Disease (AD) (Hawkes 2018). In 2021, they developed the first vaccine for Covid-19 to re...
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
    • Home | Bibliographies | About PhilArchive | Contact us | Code of conduct

    CDP Phiosophy Documentation Center
    PhilPapers logo by Andrea Andrews and Meghan Driscoll.
    This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications).

    Use of this site is subject to terms & conditions.
    All rights reserved by The PhilPapers Foundation

    Server: philpapers-web-7674574dd6-8q2d6 uwo